APP and Alzheimer disease: In addition, HA-MMSN-1F12 treatment resulted in reduced brain Aβ42 fibrils and increased soluble Aβ42 species, which were excreted through intestinal metabolism, thereby reducing the brain Aβ42 load and neuroinflammation and improving memory deficits in APP/PS1 AD mice.